Collegium Helveticum, ETH and University of Zurich, Schmelzbergstr. 25, 8092 CH-Zurich, Switzerland.
Neurobiol Learn Mem. 2011 Mar;95(3):326-34. doi: 10.1016/j.nlm.2011.01.005. Epub 2011 Jan 26.
Physiological studies of placebo-mediated suggestion have been recently performed beyond their traditional clinical context of pain and analgesia. Various neurotransmitter systems and immunological modulators have been used in successful placebo suggestions, including Dopamine, Cholecystokinin and, most extensively, opioids. We adhered to an established conceptual framework of placebo research and used the μ-opioid-antagonist Naloxone to test the applicability of this framework within a cognitive domain (e.g. memory) in healthy volunteers. Healthy men (n=62, age 29, SD=9) were required to perform a task-battery, including standardized and custom-designed memory tasks, to test short-term recall and delayed recognition. Tasks were performed twice, before and after intravenous injection of either NaCl (0.9%) or Naloxone (both 0.15 mg/kg), in a double-blind setting. While one group was given neutral information (S-), the other was told that it might receive a drug with suspected memory-boosting properties (S+). Objective and subjective indexes of memory performance and salivary cortisol (as a stress marker) were recorded during both runs and differences between groups were assessed. Short-term memory recall, but not delayed recognition, was objectively increased after placebo-mediated suggestion in the NaCl-group. Naloxone specifically blocked the suggestion effect without interfering with memory performance. These results were not affected when changes in salivary cortisol levels were considered. No reaction time changes, recorded to uncover unspecific attentional impairment, were seen. Placebo-mediated suggestion produced a training-independent, objective and Naloxone-sensitive increase in memory performance. These results indicate an opioid-mediated placebo effect within a circumscribed cognitive domain in healthy volunteers.
近年来,除了在传统的疼痛和镇痛临床环境中,安慰剂介导的暗示的生理研究也已超出其范围。各种神经递质系统和免疫调节剂已被用于成功的安慰剂暗示,包括多巴胺、胆囊收缩素和最广泛的阿片类药物。我们遵循了已建立的安慰剂研究概念框架,并使用μ-阿片受体拮抗剂纳洛酮来测试该框架在健康志愿者认知领域(例如记忆)中的适用性。健康男性(n=62,年龄 29,SD=9)需要执行一系列任务,包括标准化和定制设计的记忆任务,以测试短期记忆和延迟识别。任务在静脉注射生理盐水(0.9%)或纳洛酮(均为 0.15mg/kg)之前和之后两次进行,采用双盲设置。一组给予中性信息(S-),另一组被告知可能会接受一种具有可疑增强记忆特性的药物(S+)。在两次运行期间记录了记忆表现的客观和主观指标以及唾液皮质醇(作为应激标志物),并评估了组间差异。在 NaCl 组中,经过安慰剂介导的暗示后,短期记忆回忆客观上有所提高,但延迟识别则没有。纳洛酮特异性地阻断了暗示效应,而不干扰记忆表现。当考虑唾液皮质醇水平的变化时,这些结果没有受到影响。未观察到记录以揭示非特异性注意力损伤的反应时间变化。安慰剂介导的暗示产生了与训练无关、客观和纳洛酮敏感的记忆表现增加。这些结果表明,在健康志愿者的特定认知领域中存在阿片类药物介导的安慰剂效应。